Cargando…

Large Neutral Amino Acid Therapy Increases Tyrosine Levels in Adult Patients with Phenylketonuria: A Long-Term Study

The standard treatment for phenylketonuria (PKU) is a lifelong low-phenylalanine (Phe) diet, supplemented with Phe-free protein substitutes; however, adult patients often show poor adherence to therapy. Alternative treatment options include the use of large neutral amino acids (LNAA). The aim of thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burlina, Alessandro P., Cazzorla, Chiara, Massa, Pamela, Polo, Giulia, Loro, Christian, Gueraldi, Daniela, Burlina, Alberto B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835503/ https://www.ncbi.nlm.nih.gov/pubmed/31640267 http://dx.doi.org/10.3390/nu11102541

Ejemplares similares

The Impact of a Slow-Release Large Neutral Amino Acids Supplement on Treatment Adherence in Adult Patients with Phenylketonuria
por: Burlina, Alessandro P., et al.
Publicado: (2020)

Quality of Life (QoL) assessment in a cohort of patients with Phenylketonuria
por: Cazzorla, Chiara, et al.
Publicado: (2014)

Implementation of Second-Tier Tests in Newborn Screening for Lysosomal Disorders in North Eastern Italy
por: Burlina, Alberto B., et al.
Publicado: (2019)

Living with phenylketonuria in adulthood: The PKU ATTITUDE study
por: Cazzorla, Chiara, et al.
Publicado: (2018)

A new strategy of desensitization in mucopolysaccharidosis type II disease treated with idursulfase therapy: A case report and review of the literature
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

Newborn screening for Pompe disease in Italy: Long-term results and future challenges
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

Report of Five Years of Experience in Neonatal Screening for Mucopolysaccharidosis Type I and Review of the Literature
por: Gragnaniello, Vincenza, et al.
Publicado: (2020)

Bone disease in early detected Gaucher Type I disease: A case report
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

Newborn Screening for Fabry Disease: Current Status of Knowledge
por: Gragnaniello, Vincenza, et al.
Publicado: (2023)

Expert opinion of an Italian working group on the assessment of cognitive, psychological, and neurological outcomes in pediatric, adolescent, and adult patients with phenylketonuria
por: Manti, Filippo, et al.
Publicado: (2022)

Correction: Expert opinion of an Italian working group on the assessment of cognitive, psychological, and neurological outcomes in pediatric, adolescent, and adult patients with phenylketonuria
por: Manti, Filippo, et al.
Publicado: (2023)

Italian national consensus statement on management and pharmacological treatment of phenylketonuria
por: Burlina, Alberto, et al.
Publicado: (2021)

Clinical experience with N-carbamylglutamate in a single-centre cohort of patients with propionic and methylmalonic aciduria
por: Burlina, Alberto, et al.
Publicado: (2016)

Abnormal activation of MAPKs pathways and inhibition of autophagy in a group of patients with Zellweger spectrum disorders and X-linked adrenoleukodystrophy
por: Gragnaniello, Vincenza, et al.
Publicado: (2023)

Neonatal Expanded Screening toward lysosomal storage disorders
por: Burlina, Alberto, et al.
Publicado: (2015)

Newborn Screening for Fabry Disease in Northeastern Italy: Results of Five Years of Experience
por: Gragnaniello, Vincenza, et al.
Publicado: (2021)

Development and psychometric validation of measures to assess the impact of phenylketonuria and its dietary treatment on patients’ and parents’ quality of life: the phenylketonuria – quality of life (PKU-QOL) questionnaires
por: Regnault, Antoine, et al.
Publicado: (2015)

Nutrition, Microbiota and Role of Gut-Brain Axis in Subjects with Phenylketonuria (PKU): A Review
por: Verduci, Elvira, et al.
Publicado: (2020)

Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids
por: Concolino, D, et al.
Publicado: (2017)

Beneficial Effects of Slow-Release Large Neutral Amino Acids after a Phenylalanine Oral Load in Patients with Phenylketonuria
por: Scala, Iris, et al.
Publicado: (2021)

Erratum: Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids
por: Concolino, D, et al.
Publicado: (2017)

Large Neutral Amino Acids (LNAAs) Supplementation Improves Neuropsychological Performances in Adult Patients with Phenylketonuria
por: Scala, Iris, et al.
Publicado: (2020)

Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries
por: Bosch, Annet M, et al.
Publicado: (2015)

Large neutral amino acid status in association with P:T ratio and diet in adult and pediatric patients with phenylketonuria
por: Douglas, Teresa D., et al.
Publicado: (2019)

Unusual Evolution of Hypertrophic Cardiomyopathy in Non-Compaction Myocardium in a Pompe Disease Patient
por: Gragnaniello, Vincenza, et al.
Publicado: (2023)

Health-related quality of life in a european sample of adults with early-treated classical PKU
por: Maissen-Abgottspon, Stephanie, et al.
Publicado: (2023)

The Utility of CSF for the Diagnosis of Primary and Secondary Monoamine Neurotransmitter Deficiencies
por: Burlina, A.B., et al.
Publicado: (2017)

Newborn screening in mucopolysaccharidoses
por: Donati, Maria Alice, et al.
Publicado: (2018)

Correction to: Newborn screening in mucopolysaccharidoses
por: Donati, Maria Alice, et al.
Publicado: (2019)

Diagnostic and management practices for phenylketonuria in 19 countries of the South and Eastern European Region: survey results
por: Giżewska, Maria, et al.
Publicado: (2015)

Large Neutral Amino Acid Supplementation Exerts Its Effect through Three Synergistic Mechanisms: Proof of Principle in Phenylketonuria Mice
por: van Vliet, Danique, et al.
Publicado: (2015)

The complete European guidelines on phenylketonuria: diagnosis and treatment
por: van Wegberg, A. M. J., et al.
Publicado: (2017)

Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial
por: Muntau, Ania C., et al.
Publicado: (2021)

Aromatic L-amino Acid Decarboxylase (AADC) deficiency: results from an Italian modified Delphi consensus
por: Fusco, Carlo, et al.
Publicado: (2021)

Long-Term Metabolic Correction of Phenylketonuria by AAV-Delivered Phenylalanine Amino Lyase
por: Tao, Rui, et al.
Publicado: (2020)

Long-Term Metabolic Correction of Phenylketonuria by AAV-Delivered Phenylalanine Amino Lyase
por: Tao, Rui, et al.
Publicado: (2022)

Evaluation of Tetrahydrobiopterin Therapy with Large Neutral Amino Acid Supplementation in Phenylketonuria: Effects on Potential Peripheral Biomarkers, Melatonin and Dopamine, for Brain Monoamine Neurotransmitters
por: Yano, Shoji, et al.
Publicado: (2016)

Apparent diffusion coefficient restriction in the white matter: going beyond acute brain territorial ischemia
por: Citton, Valentina, et al.
Publicado: (2011)

Institutions and the uneven geography of the first wave of the COVID‐19 pandemic
por: Rodríguez‐Pose, Andrés, et al.
Publicado: (2021)

Survey of Italian pediatricians’ perspectives and knowledge about neonatal screening
por: Burlina, Alberto B., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_aeguun99tu27p5uvr8io3eq18t